<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01061047</url>
  </required_header>
  <id_info>
    <org_study_id>ERTAMUSCLE</org_study_id>
    <nct_id>NCT01061047</nct_id>
  </id_info>
  <brief_title>Comparison of Ertapenem Distribution in the Muscle of Six Healthy Volunteers and Six Critically Ill Patients by Microdialysis</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Poitiers University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Poitiers University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Ertapenem is an antibiotic that is highly bound to plasma protein (&gt; 95%). The effects of&#xD;
      this high protein binding on tissue distribution of antibiotics have been few evaluated yet.&#xD;
&#xD;
      In this study, two groups of subjects will be compared: 6 healthy volunteers and 6 critically&#xD;
      ill patients (patients with infection due to an Ertapenem susceptible bacteria). Indeed,&#xD;
      these 2 populations show changes in binding capacity of drugs to plasma proteins due to a&#xD;
      decrease of protidaemia and of the affinity of drugs to transport proteins.&#xD;
&#xD;
      It seems therefore important to clarify the consequences of a modification in protein binding&#xD;
      on distribution of antibiotics. That's why we have decided to characterize tissue&#xD;
      distribution of ertapenem in healthy volunteers and critically ill patients by assessing:&#xD;
      free and total concentrations in plasma and free concentrations in muscle by microdialysis.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <condition>Healthy</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ertapeneme</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age: from 18 to 80 years&#xD;
&#xD;
          -  Patients with infection due to ertapenem susceptible bacteria.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients who received ertapenem within 7 days prior to inclusion&#xD;
&#xD;
          -  Known allergy to ertapenem or any excipients&#xD;
&#xD;
          -  Neutropenia &lt; 500/mm3&#xD;
&#xD;
          -  Hemoglobin concentration &lt; 9g/dl&#xD;
&#xD;
          -  Renal failure (creatinin clearance &lt; 30ml/min/1.73m²)&#xD;
&#xD;
          -  Decompensated heart failure&#xD;
&#xD;
          -  Patients receiving vasopressor (adrenalin, noradrenalin), &gt; 0.5µg/kg/min&#xD;
&#xD;
          -  Known hypersensitivity to Elma®&#xD;
&#xD;
          -  Positive pregnancy test or currently lactating&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Poitiers University Hospital - 2 rue de la Milétrie - Réanimation chirugicale</name>
      <address>
        <city>Poitiers</city>
        <zip>86021</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>January 2010</verification_date>
  <study_first_submitted>January 29, 2010</study_first_submitted>
  <study_first_submitted_qc>February 1, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 2, 2010</study_first_posted>
  <last_update_submitted>August 28, 2012</last_update_submitted>
  <last_update_submitted_qc>August 28, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 29, 2012</last_update_posted>
  <keyword>patients infected with a bacteria sensible to ertapeneme</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

